Docoh
Loading...

IMCR Immunocore

Filed: 24 Aug 21, 4:33pm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 
FORM 6-K
 

 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the Month of August 2021
 
Commission File Number: 001-39992
 

 
Immunocore Holdings plc
(Translation of registrant’s name into English)
 


92 Park Drive
Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
 (Address of principal executive office)
 


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒  Form 20-F    ☐  Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
 
Press Release
 
On August 24, 2021, Immunocore Holdings plc issued a press release to announce the acceptance of a Biologics License Application for review by the U.S. Food and Drug Administration and a Marketing Authorization Application for review by the European Medicine Agency, respectively, for tebentafusp for the treatment of patients with metastatic uveal melanoma. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.


EXHIBIT INDEX

Exhibit
No.
 Description
   
 Press Release dated August 24, 2021.


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
  
IMMUNOCORE HOLDINGS PLC
    
Date:August 24, 2021By:
/s/ Bahija Jallal, Ph.D.
   NameBahija Jallal, Ph.D.
   Title:Chief Executive Officer